Interferon-β1b increases Th2 response in neuromyelitis optica

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 12213-12223

  Nakajima, Hideto ^a   Hosokawa, Takafumi ^a   Doi, Yoshimitu ^a   Ikemoto, Toshiyuki ^a   Ishida, Shimon ^a   Kimura, Fumiharu ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

CCR4; CCR5; Chemokine receptor; CXCR3; Ifn 1b; Multiple sclerosis; Neuromyelitis optica; Th1; Th2

Indexed keywords

ALPHA INTERFERON; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; INTERFERON ALPHA1B; INTERFERON BETA SERINE; UNCLASSIFIED DRUG; BETA INTERFERON; CCR4 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RECURRENCE RISK; TH1 CELL; TH2 CELL; DRUG ADMINISTRATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEUROMYELITIS OPTICA; PATHOLOGY;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; RECEPTORS, CCR4; RECEPTORS, CCR5; RECEPTORS, CXCR3; TH2 CELLS;

EID: 84867751680     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131012213     Document Type: Article

References (42)

1. Sørensen, T.L.; Sellebjerg, F. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis. Mult. Scler. 2002, 8, 104-107.
2. Sega, S.; Wraber, B.; Mesec, A.; Horvat, A.; Ihan, A. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines. Clin. Neurol. Neurosurg. 2004, 106, 255-258.
3. Ersoy, E.; Kuş, C.N.; Sener, U.; Coker, I.; Zorlu, Y. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur. J. Neurol. 2005, 12, 208-211.
4. Krakauer, M.; Sorensen, P.S.; Khademi, M.; Olsson, T.; Sellebjerg, F. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand. J. Immunol. 2006, 64, 155-163.
5. Shimizu, Y.; Ota, K.; Kubo, S.; Kabasawa, C.; Kobayashi, M.; Ohashi, T.; Uchiyama, S. Association of Th1/Th2-related chemokine receptors in peripheral T cells with disease activity in patients with multiple sclerosis and neuromyelitis optica. Eur. Neurol. 2011, 66, 91-97.
6. Wingerchuk, D.M.; Lennon, V.A.; Lucchinetti, C.F.; Pittock, S.J.; Weinshenker, B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6, 805-815.
7. Lucchinetti, C.F.; Mandler, R.N.; McGavern, D.; Bruck, W.; Gleich, G.; Ransohoff, R.M.; Trebst, C.; Weinshenker, B.; Wingerchuk, D.; Parisi, J.E.; et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125, 1450-1461.
8. Hosokawa, T.; Nakajima, H.; Doi, Y.; Sugino, M.; Kimura, F.; Hanafusa, T.; Takahashi, T. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of blood-brain barrier. J. Neuroimmunol. 2011, 236, 81-86.
9. Nakajima, H.; Hosokawa, T.; Sugino, M.; Kimura, F.; Sugasawa, J.; Hanafusa, T.; Takahashi, T. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol. 2010, 10, 45.
10. Lennon, V.A.; Wingerchuk, D.M.; Kryzer, T.J.; Pittock, S.J.; Lucchinetti, C.F.; Fujihara, K.; Nakashima, I.; Weinshenker, B.G. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004, 364, 2106-2112.
11. Jarius, S.; Aboul-Enein, F.; Waters, P.; Kuenz, B.; Hauser, A.; Berger, T.; Lang, W.; Reindl, M.; Vincent, A.; Kristoferitsch, W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131, 3072-3080.
12. Saida, T.; Tashiro, K.; Itoyama, Y.; Sato, T.; Ohashi, Y.; Zhao, Z. Interferon Beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: A randomized multicenter study. Neurology 2005, 64, 621-630.
13. Tanaka, M.; Tanaka, K.; Komori, M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur. Neurol. 2009, 62, 167-170.
14. Uzawa, A.; Mori, M.; Hayakawa, S.; Masuda, S.; Kuwabara, S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur. J. Neurol. 2010, 17, 672-676.
15. Simpson, J.E.; Newcombe, J.; Cuzner, M.L.; Woodroofe, M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 1998, 84, 238-249.
16. Sorensen, T.L.; Tani, M.; Jensen, J.; Pierce, V.; Lucchinetti, C.; Folcik, V.A.; Qin, S.; Rottman, J.; Sellebjerg, F.; Strieter, R.M.; et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 1999, 103, 807-815.
17. Balashov, K.E.; Rottman, J.B.; Weiner, H.L.; Hancock, W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA 1999, 96, 6873-6878.
18. Nakajima, H.; Fukuda, K.; Doi, Y.; Sugino, M.; Kimura, F.; Hanafusa, T.; Ikemoto, T.; Shimizu, A. Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Eur. Neurol. 2004, 52, 162-168.
19. Uzawa, A.; Mori, M.; Hayakawa, S.; Masuda, S.; Nomura, F.; Kuwabara, S. Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica. BMC Neurol. 2010, 10, 113.
20. Warabi, Y.; Matsumoto, Y.; Hayashi, H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci. 2007, 252, 57-61.
21. Shimizu, Y.; Yokoyama, K.; Misu, T.; Takahashi, T.; Fujihara, K.; Kikuchi, S.; Itoyama, Y.; Iwata, M. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J. Neurol. 2008, 255, 305-307.
22. Shimizu, J.; Hatanaka, Y.; Hasegawa, M.; Iwata, A.; Sugimoto, I.; Date, H.; Goto, J.; Shimizu, T.; Takatsu, M.; Sakurai, Y.; et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010, 75, 1423-1427.
23. Takahashi, T.; Fujihara, K.; Nakashima, I.; Misu, T.; Miyazawa, I.; Nakamura, M.; Watanabe, S.; Shiga, Y.; Kanaoka, C.; Fujimori J.; et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007, 130, 1235-1243.
24. Misu, T.; Fujihara, K.; Kakita, A.; Konno, H.; Nakamura, M.; Watanabe, S.; Takahashi, T.; Nakashima, I.; Takahashi, H.; Itoyama, Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: Distinction from multiple sclerosis. Brain 2007, 130, 1224-1234.
25. Rudick, R.A.; Goelz, S.E. Beta-interferon for multiple sclerosis. Exp Cell Res. 2011, 317, 1301-1311.
26. Kieseier, B.C. The mechanism of action of interferon-â in relapsing multiple sclerosis. CNS Drugs 2011, 25, 491-502.
27. Wandinger, K.P.; Stürzebecher, C.S.; Bielekova, B.; Detore, G.; Rosenwald, A.; Staudt, L.M.; McFarland, H.F.; Martin, R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001, 50, 349-357.
28. Krumbholz, M.; Faber, H.; Steinmeyer, F.; Hoffmann, L.A.; Kümpfel, T.; Pellkofer, H.; Derfuss, T.; Ionescu, C.; Starck, M.; Hafner, C.; et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131, 1455-1463.
29. Jonsson, M.V.; Szodoray, P.; Jellestad, S.; Jonsson, R.; Skarstein, K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J. Clin. Immunol. 2005, 25, 189-201.
30. Stohl, W.; Metyas, S.; Tan, S.M.; Cheema, G.S.; Oamar, B.; Xu, D.; Roschke, V.; Wu, Y.; Baker, K.P.; Hilbert, D.M. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis. Rheum. 2003, 48, 3475-3486.
31. Krumbholz, M.; Specks, U.; Wick, M.; Kalled, S.L.; Jenne, D.; Meinl, E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 2005, 25, 298-302.
32. Palace, J.; Leite, M.I.; Nairne, A.; Vincent, A. Interferon Beta treatment in neuromyelitis optica: Increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 2010, 67, 1016-1017.
33. Karni, A.; Balashov, K.; Hancock, W.W.; Bharanidharan, P.; Abraham, M.; Khoury, S.J.; Weiner, H.L. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J. Neuroimmunol. 2004, 146, 189-198.
34. Acosta-Rodriguez, E.V.; Rivino, L.; Geginat, J.; Jarrossay, D.; Gattorno, M.; Lanzavecchia, A.; Sallusto, F.; Napolitani, G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 2007, 8, 639-646.
35. Lim, H.W.; Lee, J.; Hillsamer, P.; Kim, C.H. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J. Immunol. 2008, 180, 122-129.
36. Axtell, R.C.; Raman, C.; Steinman, L. Interferon-β exacerbates Th17-mediated inflammatory disease. Trends. Immunol. 2011, 32, 272-277.
37. Ishizu, T.; Osoegawa, M.; Mei, F.J.; Kikuchi, H.; Tanaka, M.; Takakura, Y.; Minohara, M.; Murai, H.; Mihara, F.; Taniwaki, T.; et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128, 988-1002.
38. Wingerchuk, D.M.; Lennon, V.A.; Pittock, S.J.; Lucchinetti, C.F.; Weinshenker, B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66, 1485-1489.
39. McDonald, W.I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H.P.; Lublin, F.D.; McFarland, H.F.; Paty, D.W.; Polman, C.H.; Reingold, S.C.; et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121-127.
40. Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983, 33, 1444-1452.
41. Nakajima, H.; Sugino, M.; Kimura, F.; Hanafusa, T.; Ikemoto, T.; Shimizu, A. Increased Intrathecal Chemokine Receptor CCR2 Expression in Multiple Sclerosis. Biomark. Insights 2007, 2, 463-468.
42. Nakajima, H.; Sugino, M.; Kimura, F.; Hanafusa, T.; Ikemoto, T.; Shimizu, A. Decreased CD14+CCR2+ monocytes in active multiple sclerosis. Neurosci. Lett. 2004, 363, 187-189.